Please use one of the following formats to cite this article in your essay, paper or report: APA. Meštrović, Tomislav. (2023, July 01). Paclitaxel Side-Effects.

We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer.We enrolled 4950 women with axillary ly ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Meštrović, Tomislav. (2023, May 13). How Paclitaxel Works.

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

They add that paclitaxel-based devices “may be the best treatment for some patients, particularly those judged to be at particularly high risk for restenosis and repeat femoropopliteal interventions,” ...

The approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868, in which KEYTRUDA plus carboplatin and paclitaxel followed by KEYTRUDA alone reduced the risk of disease ...

The US National Cancer Institute screened 35,000 plants, but one particular sample collected from the bark of the Pacific Yew tree provided what is now one of the most highly prescribed cancer drugs.

The United States Food and Drug Administration today, in a letter to healthcare providers, reversed its restrictions on the use of paclitaxel-based therapies in peripheral vascular interventions (PVIs ...

A total of 469 weekly paclitaxel infusions were administered to 30 patients (median, 14 infusions/patient). The median delivered dose-intensity was 91 mg/m2/wk (range, 80 to 108). The overall response ...

Among 494 patients who had undergone randomization, overall survival was significantly longer with trastuzumab deruxtecan than with ramucirumab plus paclitaxel (median, 14.7 vs. 11.4 months ...

Between then and now, the FDA continued to approve paclitaxel-coated devices, such as Boston Scientific’s Ranger balloon in 2020.It’s designed to limit the patient’s systemic exposure to the ...

The statement comes 4 years after the agency's first warnings of a mortality risk from paclitaxel-based peripheral stents and balloons, the controversy ignited by a 2018 meta-analysis.